Healthcare equity advocates have long suspected that racial disparities extend far beyond access to care, affecting treatment quality and outcomes even within universal systems. This comprehensive analysis of Brazil's public healthcare database reveals how deeply embedded these inequities remain, even when cost barriers are theoretically removed. Examining 670,205 prostate cancer patients over 16 years, researchers documented systematic differences in both disease presentation and treatment delivery between White and non-White men. Non-White patients consistently presented with more advanced disease stages and received different treatment approaches, with White men more likely to receive localized therapy for early-stage disease while non-White men received such therapy primarily for later-stage cancers. The treatment patterns suggest a troubling paradox: despite Brazil's universal healthcare system covering 77% of the population, racial minorities face inferior care pathways. Most concerning was the finding that only 17.8% of advanced-stage patients received modern docetaxel chemotherapy, while outdated therapies like first-generation antiandrogens remained widely used. This represents a significant departure from current evidence-based standards that favor newer, more effective treatments. The implications extend beyond Brazil's borders, as this pattern likely reflects similar disparities in other developing nations with universal healthcare systems. The $1.83 billion expenditure data suggests that inferior treatment isn't necessarily cheaper treatment, raising questions about resource allocation efficiency. For health-conscious adults, this research underscores that even well-intentioned healthcare systems can perpetuate disparities through subtle institutional biases, emphasizing the importance of advocating for standardized, evidence-based care protocols regardless of demographic factors.